Literature DB >> 19900229

Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks.

A Onat1, G Hergenç, E Ayhan, M Uğur, H Kaya, M Tuncer, G Can.   

Abstract

AIMS: We studied determinants of serum apolipoprotein C-III (apoC-III) and whether levels of apoC-III or its fractions predict metabolic syndrome (MetS), Type 2 diabetes and coronary heart disease (CHD).
METHODS: The predictive value of apoC-III, measured by immunoturbimetric immunoassay in 802 tracked individuals of a Turkish general population in determining cardiometabolic risk was assessed over 4.4 +/- 1.2 years' follow-up. Patients with MetS, Type 2 diabetes and CHD at baseline were excluded.
RESULTS: Total apoC-III, as well as both fractions, was significantly, linearly and inversely related to smoking status, positively to alcohol usage and to levels of complement C3. Mid and high tertiles of total or non-high density lipoprotein (HDL) apoC-III predicted significantly and independently incident MetS; they predicted CHD with risk ratios of 1.6 [95% confidence intervals (CI) 1.02-2.5], for 1 sd increment, after adjustments that included HDL cholesterol and body mass index (BMI). The highest tertile of HDL apoC-III was a major independent predictor of new-onset diabetes with a 2.5-fold risk ratio for 1 sd increment (95% CI 1.5-4.0) in combined sexes, after adjustment for waist circumference, HDL cholesterol and other confounders and was a better predictor than waist girth.
CONCLUSIONS: Serum total apoC-III or its fractions are linearly and inversely associated with smoking, positively with alcohol usage and serum complement C3. The presumably dysfunctional HDL apoC-III is a stronger predictor of Type 2 diabetes than waist girth in Turks. Non-HDL apoC-III predicts strongly the development of MetS as well as incident CHD, independent of HDL cholesterol, BMI and non-lipid factors. The atherogenicity of apoC-III and dysfunctionality of HDL apoC-III carry huge public health implications in Turks.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19900229     DOI: 10.1111/j.1464-5491.2009.02814.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  12 in total

1.  Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Sarah A Aroner; Jeremy D Furtado; Frank M Sacks; Michael Y Tsai; Kenneth J Mukamal; Robyn L McClelland; Majken K Jensen
Journal:  Diabetologia       Date:  2019-04-04       Impact factor: 10.122

2.  Development of a sensitive ELISA to quantify apolipoprotein CIII in nonhuman primate serum.

Authors:  Yuxin Wang; Zhili Song; Janice D Wagner; Catherine Pachuk; Romesh R Subramanian
Journal:  J Lipid Res       Date:  2011-03-02       Impact factor: 5.922

Review 3.  Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.

Authors:  Alison B Kohan
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-04       Impact factor: 3.243

4.  Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease.

Authors:  Beatriz Talayero; Liyun Wang; Jeremy Furtado; Vincent J Carey; George A Bray; Frank M Sacks
Journal:  J Lipid Res       Date:  2014-06-25       Impact factor: 5.922

5.  Association between protein signals and type 2 diabetes incidence.

Authors:  Troels Mygind Jensen; Daniel R Witte; Damiana Pieragostino; James N McGuire; Ellis D Schjerning; Chiara Nardi; Andrea Urbani; Mika Kivimäki; Eric J Brunner; Adam G Tabàk; Dorte Vistisen
Journal:  Acta Diabetol       Date:  2012-02-05       Impact factor: 4.280

6.  HDL Containing Apolipoprotein C-III is Associated with Insulin Sensitivity: A Multicenter Cohort Study.

Authors:  Rain Yamamoto; Majken K Jensen; Sarah Aroner; Jeremy D Furtado; Bernard Rosner; Frank B Hu; Beverley Balkau; Andrea Natali; Ele Ferrannini; Simona Baldi; Frank M Sacks
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

7.  Sex differences in HDL ApoC-III in American Indian youth.

Authors:  Piers R Blackett; Sohail Khan; Wenyu Wang; Petar Alaupovic; Elisa T Lee
Journal:  Biol Sex Differ       Date:  2012-08-16       Impact factor: 5.027

8.  Dynamics in Cardiometabolic Risk among Turkish Adults: Similarities to that in Iranians?

Authors:  Altan Onat
Journal:  Int J Prev Med       Date:  2011-04

9.  Moderate alcohol consumption and lipoprotein subfractions: a systematic review of intervention and observational studies.

Authors:  Trine L Wilkens; Kaare Tranæs; Jane N Eriksen; Lars O Dragsted
Journal:  Nutr Rev       Date:  2022-04-08       Impact factor: 6.846

10.  HDL Glycoprotein Composition and Site-Specific Glycosylation Differentiates Between Clinical Groups and Affects IL-6 Secretion in Lipopolysaccharide-Stimulated Monocytes.

Authors:  Sridevi Krishnan; Michiko Shimoda; Romina Sacchi; Muchena J Kailemia; Guillaume Luxardi; George A Kaysen; Atul N Parikh; Viviane N Ngassam; Kirsten Johansen; Glenn M Chertow; Barbara Grimes; Jennifer T Smilowitz; Emanual Maverakis; Carlito B Lebrilla; Angela M Zivkovic
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.